Table 2 Temporal Trends in FISH Test and Trastuzumab Utilization
|  | Total % (n = 766) | Before covered by basic medical insurance | Covered by insurance but not available in JX city | Available in JX city | Price reduced to $817 per dose |
|---|---|---|---|---|---|
Before Oct 2017 (n = 227) | Oct 2017-Feb 2019(n = 127) | Mar 2019-Dec 2019 (n = 166) | After Jan 2020 (n = 246) | ||
Identified Trastuzumab-eligible patients (CerbB2 3 +) | n = 271 | n = 99 | n = 68 | n = 31 | n = 73 |
 Treated with Trastuzumab | 68.27 | 40.40 | 77.94 | 83.87 | 90.41 |
 Not treated with Trastuzumab | 31.73 | 59.60 | 22.06 | 16.13 | 9.59 |
Patients needed further confirmation through FISH tests (CerbB2 2 +) | n = 495 | n = 128 | n = 59 | n = 135 | n = 173 |
 Patients had FISH tests | n = 154 (31.11%) | n = 0 (0.00%) | n = 0 (0.00%) | n = 12 (8.89%) | n = 142 (82.08%) |
  Patients with positive results | n = 43 | n = 0 | n = 0 | n = 2 | n = 40 |
  Treated with Trastuzumab | 83.72 | – | – | 0 | 87.50 |
  Not treated with Trastuzumab | 16.28 | – | – | 100 | 12.50 |
 Patients did NOT have FISH tests | n = 341 (68.89%) | n = 128 (100.00%) | n = 59 (100.00%) | n = 123 (91.11%) | n = 31 (17.92%) |
  Treated with Trastuzumab | 13.78 | 11.72 | 18.64 | 14.63 | 9.68 |
  Not treated with Trastuzumab | 86.22 | 88.28 | 81.36 | 85.37 | 90.32 |